BIGH3-related corneal dystrophies are a group of potentially blinding inherited corneal disorders that have been attributed to more than 30 missense mutations of BIGH3 gene in 5q3l of humans. These dystrophies are characterized by stromal amyloid and/or non-amyloid deposits, and painful recurrent corneal erosions due to poor epithelial adhesions. Corneal transplantation or phototherapeutic keratectomy (PTK) is often needed to remove corneal opacities and scars. These therapeutic options offer only temporary relief and cannot prevent recurrences, thereby necessitating other non-invasive yet effective, alternative treatments In this proposal, we intend to employ novel synthetic peptides, known as Meptides (N-methylated peptide), to prevent the abnormal amyloid fibril aggregations in BIGHS-related corneal dystrophies. The therapeutic potential of meptides has been demonstrated in Alzheimer's disease. Meptides with their relatively small size and sequence-specific inhibition of amyloidogenic region offer greater advantages over other therapeutic options such as amyloid-specific antibody or nonspecific amyloid-interfering compounds. We have identified and synthesized two meptides specifically targeting one of the amyloidogenic regions of BIGH3. Our preliminary studies with Thioflavin T fluorescence assay and electron microscopy demonstrated that these meptides successfully suppressed amyloid fibril formation in vitro. We will further modify the compositions of meptides for optimal inhibition of amyloid aggregations and investigate their bioavailability, potential toxicities and immune response in corneal tissues with cultured corneal cells, organ cultures and animal models. The knowledge thus learned from meptide-mediated perturbation of protein aggregations should facilitate further understanding of the abnormal protein aggregations in BIGHS-related corneal dystrophies and serve as a foundation for developing future therapies for BIGHS-related corneal dystrophies and other conformational diseases related to protein misfolding. ? ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21EY017852-01
Application #
7176987
Study Section
Anterior Eye Disease Study Section (AED)
Program Officer
Shen, Grace L
Project Start
2007-03-01
Project End
2009-02-28
Budget Start
2007-03-01
Budget End
2008-02-29
Support Year
1
Fiscal Year
2007
Total Cost
$186,875
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Ophthalmology
Type
Schools of Medicine
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Grothe, Heather L; Little, Morgan R; Sjogren, Phayvanh P et al. (2013) Altered protein conformation and lower stability of the dystrophic transforming growth factor beta-induced protein mutants. Mol Vis 19:593-603
Nelson, Elizabeth F; Huang, Craig W; Ewel, Jillian M et al. (2012) Halofuginone down-regulates Smad3 expression and inhibits the TGFbeta-induced expression of fibrotic markers in human corneal fibroblasts. Mol Vis 18:479-87
Grothe, Heather L; Little, Morgan R; Cho, Angela S et al. (2009) Denaturation and solvent effect on the conformation and fibril formation of TGFBIp. Mol Vis 15:2617-26